Overview

Phase II/III Study of Anti-VEGF in Neovascular AMD

Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Eyetech Pharmaceuticals
Treatments:
Bevacizumab